Evidence map›Paper›PMID 31671775›Full record

ArticleDiagnostics (Basel, Switzerland)2019

Comparison of Commercial ELISA Kits, a Prototype Multiplex Electrochemoluminescent Assay, and a Multiplex Bead-Based Immunoassay for Detecting a Urine-Based Bladder-Cancer-Associated Diagnostic Signature.

Hideki Furuya, Ian Pagano, Keanu Chee, Takashi Kobayashi, Regan S Wong, Riko Lee, Charles J Rosser

Abstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  2. Article
  3. Article
  4. Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025
    Review
  5. The role of angiogenin in bladder cancer: where are we in 2025?International urology and nephrology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hideki FuruyaDivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Hideki.Furuya@cshs.org.
Ian PaganoCancer Prevention in the Pacific Program University of Hawaii Cancer Center, Honolulu, HI 96813, USA. pagano@hawaii.edu.ORCID 0000-0002-6248-0113
Keanu CheeTranslational and Clinical Research Program University of Hawaii Cancer Center, Honolulu, HI 96813, USA. kchee13@punahou.edu.
Takashi KobayashiDepartment of Urology, Kyoto University, Kyoto 606-8507, Japan. selecao@kuhp.kyoto-u.ac.jp.ORCID 0000-0003-1069-2816
Regan S WongDivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. rwongega@ucla.edu.
Riko LeeTranslational and Clinical Research Program University of Hawaii Cancer Center, Honolulu, HI 96813, USA. riholee@hawaii.edu.
Charles J RosserDivision of Urology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. charles.rosser@cshs.org.ORCID 0000-0002-6052-4223

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
VALIDATION OF A MULTIPLEXED ASSAY FOR BLADDER CANCER DIAGNOSISR01CA198887 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI ROSSER, CHARLES J · 2016 to 2025
$6.8M
NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA198887
6 · The paper itself

Abstract

The ability to accurately measure multiple proteins simultaneously in a single assay has the potential to markedly improve the efficiency of clinical tests composed of multiple biomarkers. We investigated the diagnostic accuracy of the two multiplex protein array platforms for detecting a bladder-cancer-associated diagnostic signature in samples from a cohort of 80 subjects (40 with bladder cancer). Banked urine samples collected from Kyoto and Nara Universities were compared to histologically determined bladder cancer. The concentrations of the 10 proteins (A1AT; apolipoprotein E-APOE; angiogenin-ANG; carbonic anhydrase 9-CA9; interleukin 8-IL-8; matrix metalloproteinase 9-MMP-9; matrix metalloproteinase 10-MMP10; plasminogen activator inhibitor 1-PAI-1; syndecan-SDC1; and vascular endothelial growth factor-VEGF) were monitored using two prototype multiplex array platforms and an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's technical specifications. The range for detecting each biomarker was improved in the multiplex assays, even though the lower limit of quantification (LLOQ) was typically lower in the commercial ELISA kits. The area under the receiver operating characteristics (AUROC) of the prototype multiplex assays was reported to be 0.97 for the multiplex bead-based immunoassay (MBA) and 0.86 for the multiplex electrochemoluminescent assay (MEA). The sensitivities and specificities for MBA were 0.93 and 0.95, respectively, and for MEA were 0.85 and 0.80, respectively. Accuracy, positive predictive values (PPV), and negative predictive values (NPV) for MBA were 0.94, 0.95, and 0.93, respectively, and for MEA were 0.83, 0.81, and 0.84, respectively. Based on these encouraging preliminary data, we believe that a multiplex protein array is a viable platform that can be utilized as an efficient and highly accurate tool to quantitate multiple proteins within biologic specimens.

Indexed as

biomarkersbladder cancermultiplexproteinurine

Identifiers

PMID31671775
PMCPMC6963675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.